CKD-5 a novel pan-histone deacetylase inhibitor synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma

摘要

Anti-tumor effects of CKD-5 on SNU-761 and SNU-3085 after a 24-h and b 48-h incubation. CKD-5 treatment significantly attenuated HCC cell proliferation in both normoxic and hypoxic conditions in a dose-dependent manner